Kallyope

Kallyope Overview

Founded 2014
Founded
Status Private
Employees 61
Employees
Latest Deal Type Series C
Latest Deal Amount $112M
Latest Deal Amount
Investors 13

Kallyope General Information

Description

Operator of a biotechnology platform intended to unlock the therapeutic and nutritional product potential of the gut-brain axis. The company's platform integrates cutting-edge technologies in sequencing, bioinformatics, neural imaging, cellular and molecular biology and human genetics, enabling healthcare industries to understand gut-brain biology that will lead to transformational therapeutics to improve human health and nutrition.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • 430 East 29th Street
  • 10th Floor
  • New York, NY 10016
  • United States
+1 (646) 000-0000

Kallyope Timeline

2017201820192020
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Kallyope Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Later Stage VC (Series C) 25-Mar-2020 $112M 00000 00000 Completed Startup
2. Early Stage VC (Series B) 05-Dec-2018 0000 00000 00000 Completed Startup
1. Early Stage VC (Series A) 10-Dec-2015 $44M $44M 0000 Completed Startup

Kallyope Cap Table

To view Kallyope‘s complete cap table, request access >>
Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C 00,000,000 00.000000 00 00 00 00 00 00.000
Series B 00,000,000 00.000000 00 00 00 00 00 00.000
Series A 44,050,000 $0.001000 8% $1 $1 1x $1 28.6%

Kallyope Competitors (17)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing
Amount
Second Genome Venture Capital-Backed South San Francisco, CA 00 000.00 0000000000 000.00
00000 000000000000 Venture Capital-Backed Waltham, MA 00 000.00 00000000000 000.00
00000 000000000000 Formerly VC-backed Cambridge, MA 000 00000 000000000 00000
000000000 00000000 Formerly VC-backed Utrecht, Netherlands 00 00.00 000000&0 00.00
000000 00000000000 Formerly VC-backed South San Francisco, CA 000 00000 000000 - 000 00000

Kallyope Executive Team (9)

Name Title Board Seat Contact Info
Nancy Thornberry Chief Executive Officer & Board Member
Juha Lauren Ph.D Chief Business Officer
Charles Zuker Ph.D Co-Founder
Richard Axel MD Co-Founder
Maximilian Lombardo Senior Data Research Associate

Kallyope Board Members (9)

To view Kallyope‘s full board member team, request access >>
Name Representing Role Since
Amy Schulman JD Polaris Partners Board Member 000 0000
Joshua Wolfe Lux Capital Management Board Member 000 0000
Nancy Thornberry Kallyope Chief Executive Officer & Board Member 000 0000
Peter Hecht Ph.D Self Board Member 000 0000
Terry McGuire Self Board Member & Strategic Advisor 000 0000

Kallyope Investors (13)

To view Kallyope‘s full investor history, request access >>
Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Casdin Capital Hedge Fund Minority 000 0000 000000 0
Greenspring Associates Venture Capital Minority 000 0000 000000 0
Columbia Technology Ventures University Minority 000 0000 000000 0
Euclidean Capital Other Minority 000 0000 000000 0
Two Sigma Ventures Corporate Venture Capital Minority 000 0000 000000 0

Ready to get started?

Request a free trial